Re: Re: Advair? Thanks Torsten

[Guest guest]

Dana,

I am sorry is having such a rough time. It must be hard during the

holidays. Is it good that she coughs to get the stuff up? Sounds like it would

be but.........who could tolerate all of that gaging and throwing up? That must

be so hard on her. It makes your stomach sore when you throw up. Her throat must

be raw too. I hope she is able to enjoy Thanksgiving..

We are off to my mom and dads.

I never did hear back from Ambry about Caden's results.

Take care,

Krystena s

Caden 4 yrs GAII

Article on Advair

>

> CHEST: Cost-Effectiveness Analysis Suggests Advair

> (Fluticasone/Salmeterol) Associated with Lower Costs than Budesonide

> Plus Formoterol "

> By Peggy Peck Special to DG News SAN DIEGO, CA -- November 5, 2002 -

- A

> cost-effectiveness analysis found that the asthma management

combination

> fluticasone Advair =AE (fluticasone/salmeterol) is more cost

effective

> than budesonide plus formoterol. Laureen Rance, MD of

GlaxoKline,

> Canada, and colleagues used data collected from a Norwegian

prospective

> multi-center study comparing fluticasone/salmeterol (FS) and

budesonide

> (BUD)plus formoterol (FORM) to model projected Canadian costs. The

> European multicenter, 12-week, randomised, controlled trial enrolled

> adult asthmatics who were symptomatic on 1000 to 1600 =B5g inhaled

> beclomethasone (or equivalent). The researchers randomised 212

patients

> to FS at doses of 250/50 =B5g bid and 216 patients to BUD 800 =B5g

bid

> plus FORM 12 =B5g bid. The researchers also collected non-protocol

> mandated asthma-related healthcare utilisation data during the

trial.

> Canadian costs were applied to the secondary effectiveness measures:

> symptom-free nights, symptom-free days, episode-free days, and weeks

> with greater than 5 percent improvement from baseline in morning

PEF.

> The primary objective of showing non-inferiority was met as the

primary

> outcome morning PEF, as F/S produced similar results to BUD+FORM

> (p=3D0.593). Patients in the F/S arm had significantly more symptom-

free

> nights (p<0.05) and significantly fewer exacerbations than those in

the

> BUD+FORM arm. The F/S group had lower total daily asthma management

> costs ($3.60 per patient) than the BUD+FORM group ($4.96 per

patient).

> The BUD+FORM group had a higher number of asthma-related

> hospitalisations, which resulted in higher mean treatment costs in

that

> arm, she said. The study was funded by GlaxoKline, Canada.